IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
InflaRx N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$1.45+0.13 (+9.85%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
-24677.9%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -82.3% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 16.83 | 8.54 | 4.13 | |
| Interest coverage | – | – | – | |
| Diluted shares | 0M | 27M | 67M |
Cash use needs five years of cash flow figures
InflaRx does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-€35.31M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-€35.31M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.06 → 4.13
- No dilutionShare count did not rise59M → 67M
- Gross margin improvedGross margin up on the prior year-1900.76% → -24677.94%
- More efficientAsset turnover rose0.00 → 0.00